Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06626230 · ClinicalTrials.gov registry record · Phase 1
Safety of Anal Curcumin
A Phase 1 study of Anal High-grade Squamous Intraepithelial Lesion, sponsored by Lisa Flowers.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 2
- Study locations
NCT06626230 is a Phase 1 study of Anal High-grade Squamous Intraepithelial Lesion that is actively recruiting participants, run by Lisa Flowers. The registered enrollment target is 48 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06626230, a Phase 1 study of Anal High-grade Squamous Intraepithelial Lesion, is actively recruiting participants, sponsored by Lisa Flowers.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgical excision (cutting out the abnormal cells)), which have potential short- and long-term side effects.
Conditions Studied
Interventions
- DRUG Curcuminoid Capsules
Study Locations (2)
Georgia
- Grady Memorial Hospital - Atlanta
- Grady Hospital - Ponce De Leon Clinic - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-03-17 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06626230
The ClinicalTrials.gov registry entry for NCT06626230 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lisa Flowers, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Anal High-grade Squamous Intraepithelial Lesion appearing as the primary indexed condition, and to 1 intervention - of which Curcuminoid Capsules is the first listed.
NCT06626230 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06626230 about?
NCT06626230 is a clinical study titled "Safety of Anal Curcumin". The purpose of this study is to see if curcumin can reverse anal high-grade squamous intraepithelial lesions (aHSIL) (high-grade anal precancerous cells or high-grade abnormal cells) in people living with HIV to avoid current treatments such as ablation (destroying abnormal cells with heat or surgic...
What is the current status of trial NCT06626230?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-03-17. Estimated completion is 2026-01.
What conditions does trial NCT06626230 study?
This clinical trial studies the following conditions: Anal High-grade Squamous Intraepithelial Lesion.
What interventions are being tested in trial NCT06626230?
The interventions under investigation include: Curcuminoid Capsules (DRUG).
Who is sponsoring clinical trial NCT06626230?
This trial is sponsored by Lisa Flowers, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06626230 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anal High-grade Squamous Intraepithelial Lesion
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.